Eduardo Bruno Martins net worth and biography

Eduardo Martins Biography and Net Worth

Chief Medical Officer of Sagimet Biosciences

Dr. Martins joined Sagimet in February 2021, bringing more than 20 years of experience as a leader in the US and global biopharmaceutical industry. Dr. Martins has worked in various therapeutic areas, including hepatology, vaccines, allergy and immunology, orphan diseases, and oncology, from translational research to Phase 4 clinical studies. His previous experience includes leadership of large-scale multinational clinical trials as well as building and leading multifunctional global teams in large pharmaceutical and small biotechnology companies. Most recently at AbbVie, Dr. Martins was vice president of clinical development and led the clinical development of cenicriviroc for nonalcoholic steatohepatitis (NASH) and a collaboration with Verily (an Alphabet company) on artificial intelligence and virtual staining applied to liver biopsy. Prior to joining AbbVie, Dr. Martins served as vice president of clinical development at Allergan. Previously, he was a member of the executive leadership team as senior vice president of liver and infectious disease drug development at Eiger Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on development of therapies for the treatment of chronic hepatitis D and orphan diseases. Prior to that, he held leadership positions at Gilead Sciences; Genentech; Dynavax Technologies; Intermune; SciClone Pharmaceuticals; University Hospital, Federal University of Rio de Janeiro, Brazil; and the Organisation Mondiale d’Endoscopie Digestive. He holds a doctorate (DPhil) degree from the University of Oxford (UK) and an MD from Federal University of Rio de Janeiro (Brazil).

What is Eduardo Bruno Martins' net worth?: The estimated net worth of Eduardo Bruno Martins is at least $679.04 thousand as of July 21st, 2025. Dr. Martins owns 106,936 shares of Sagimet Biosciences stock worth more than $679,044 as of December 4th. This net worth approximation does not reflect any other assets that Dr. Martins may own. Additionally, Dr. Martins receives an annual salary of $649,330.00 as Chief Medical Officer at Sagimet Biosciences. Learn More about Eduardo Bruno Martins' net worth.
How old is Eduardo Bruno Martins?: Dr. Martins is currently 61 years old. There are 4 older executives and no younger executives at Sagimet Biosciences. The oldest executive at Sagimet Biosciences is Dr. George W. Kemble Ph.D., Executive Chairman of the Board, who is 62 years old. Learn More on Eduardo Bruno Martins' age.
What is Eduardo Bruno Martins' salary?: As the Chief Medical Officer of Sagimet Biosciences Inc., Dr. Martins earns $649,330.00 per year. The highest earning executive at Sagimet Biosciences is Mr. David A. Happel, CEO, President & Director, who commands a salary of $836,180.00 per year. Learn More on Eduardo Bruno Martins' salary.
How do I contact Eduardo Bruno Martins?: The corporate mailing address for Dr. Martins and other Sagimet Biosciences executives is , , . Sagimet Biosciences can also be reached via phone at 650-561-8600 and via email at [email protected]. Learn More on Eduardo Bruno Martins' contact information.
Has Eduardo Bruno Martins been buying or selling shares of Sagimet Biosciences?: Eduardo Bruno Martins has not been actively trading shares of Sagimet Biosciences over the course of the past ninety days. Most recently, Eduardo Bruno Martins sold 8,277 shares of the business's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $9.13, for a transaction totalling $75,569.01. Following the completion of the sale, the insider now directly owns 106,936 shares of the company's stock, valued at $976,325.68. Learn More on Eduardo Bruno Martins' trading history.
Who are Sagimet Biosciences' active insiders?: Sagimet Biosciences' insider roster includes David Happel (Chief Executive Officer & Director), George Kemble (Chairman), Eduardo Martins (Chief Medical Officer), Elizabeth Rozek (General Counsel), and Beth Seidenberg (Director). Learn More on Sagimet Biosciences' active insiders.
Are insiders buying or selling shares of Sagimet Biosciences?: During the last twelve months, insiders at the sold shares 4 times. They sold a total of 122,223 shares worth more than $1,061,625.27. The most recent insider tranaction occured on November, 20th when Chairman George Kemble sold 37,688 shares worth more than $289,820.72. Insiders at Sagimet Biosciences own 14.7% of the company. Learn More about insider trades at Sagimet Biosciences.
Information on this page was last updated on 11/20/2025.

Eduardo Bruno Martins Insider Trading History at Sagimet Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/21/2025	Sell	8,277	$9.13	$75,569.01	106,936
7/19/2024	Sell	8,357	$3.10	$25,906.70	81,213

Eduardo Bruno Martins Buying and Selling Activity at Sagimet Biosciences

Sagimet Biosciences Company Overview

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Today's Range

Now: $6.35

$6.19

$6.55

50 Day Range

MA: $7.56

$6.09

$9.14

2 Week Range

Now: $6.35

$1.73

$11.41

Volume

809,338 shs

Average Volume

478,418 shs

Market Capitalization

$206.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.32

Eduardo Martins Biography and Net Worth

What is Eduardo Bruno Martins' net worth?

How old is Eduardo Bruno Martins?

What is Eduardo Bruno Martins' salary?

How do I contact Eduardo Bruno Martins?

Has Eduardo Bruno Martins been buying or selling shares of Sagimet Biosciences?

Who are Sagimet Biosciences' active insiders?

Are insiders buying or selling shares of Sagimet Biosciences?